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Abstract
Background: Phosphatidylcholine (PPC) formulation is used for lipolytic injection, even though its mechanism of
action is not well understood.
Methods: The viability of 3T3-L1 pre-adipocytes and differentiated 3T3-L1 cells was measured after treatment of
PPC alone, its vehicle sodium deoxycholate (SD), and a PPC formulation. Western blot analysis was performed to
examine PPC-induced signaling pathways.
Results: PPC, SD, and PPC formulation significantly decreased 3T3-L1 cell viability in a concentration-dependent
manner. PPC alone was not cytotoxic to CCD-25Sk human fibroblasts at concentrations <1 mg/ml, whereas SD and
PPC formulation were cytotoxic. Western blot analysis demonstrated that PPC alone led to the phosphorylation of
the stress signaling proteins, such as p38 mitogen-activated protein kinase and c-Jun N-terminal kinase, and
activated caspase-9, -8, -3 as well as cleavage of poly(ADP-ribose) polymerase. However, SD did not activate the
apoptotic pathways. Instead, SD and PPC formulation induced cell membrane lysis, which may lead to necrosis of
cells.
Conclusions: PPC results in apoptosis of 3T3-L1 cells.
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Background
Mesotherapy is a new technique of injecting drugs into
the mesoderm for the treatment of local conditions [1].
This method allows the use of increased concentration of
drugs and can produce greater treatment effects.
Mesotherapy has been used for many infirmities, such as
fat emboli, chronic pain, hyperlipidemia, and liver pro-
blems [2]. Phosphatidycholine (PPC) formulation has
been widely-used to dissolve local fat deposits as a safe
nonsurgical alternative to liposuction [3]. Many clinical
studies have reported that the subcutaneous injection of
PPC formulation reduces fat [3-5]. Although the bio-
chemical mechanisms are very poorly studied, it has been
suggested that no enzymatic lipolytic pathway is involved
[6]. Thus, it is thought that the PPC formulation
dissolves local fat deposits in a nonspecific manner [7].
PPC formulation has not been approved by the Food and
Drug Administration (FDA) for use in lipodissolution.
PPC is a lecithin-derived phospholipid [4], which is
widely-distributed in human cell membranes [8]. The
Lands cycle and the Kennedy pathway are two pathways
of PPC synthesis [9], and they take place in the endo-
plasmic reticulum [10]. Increased PPC in cell mem-
branes can accelerate lipolysis by improving sensitivity
to insulin [5,11]. In addition, PPC is the major phospho-
lipid in pulmonary surfactant [12]. On the other hand,
PPC induces apoptosis of hepatic cancer cells [13].
Moreover, the size of lipomas is reduced after intrale-
sional injection of PPC [14].
Obesity is one of the main health problems in much
of the Western world, as a consequence of the induction
of various metabolic derangements including dyslipide-
mia, hypertension, glucose intolerance, and hepatic stea-
tosis [15]. Obesity is identified by increased number and
size of adipocytes [16]. Adipocytes, which store excess
* Correspondence: ds_kim@cau.ac.kr
† Contributed equally
1Departments of Biochemistry, Chung-Ang University College of Medicine,
221 Heukseok-dong, Dongjak-gu, Seoul 156-756, Republic of Korea
Full list of author information is available at the end of the article
Li et al. Journal of Biomedical Science 2011, 18:91
http://www.jbiomedsci.com/content/18/1/91
© 2011 Li et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
energy, release paracrine factors that induce growth and
differentiation of neighboring pre-adipocytes [17].
Therefore, both suppression of pre-adipocyte differentia-
tion and decrease in cell viability of pre-adipocytes and
adipocytes are possible ways to treat obesity. To date,
many studies have focused on the inhibition of adipo-
genesis. However, the notable ability of adipocytes to
resist apoptosis is poorly understood [18].
Cell death, including apoptosis and necrosis, are fol-
lowed by the cleavage of proteins and DNA [19]. These
two pathways of cell death are associated with different
patterns of nuclear protein cleavage [20]. For example,
poly(ADP-ribose) polymerase (PARP) cleavage generates
an 85 kD fragment during apoptosis but generates a 50
kD fragment in necrotic cell death [21]. Caspase-3 is an
apoptotic signal transducer in 3T3-L1 pre-adipocytes
[22].
In the present study, PPC formulations containing
PPC and sodium deoxycholate (SD) were used. SD is a
secondary bile salt and is used as a laboratory detergent
to dissolve PPC [7]. Physiologically, however, SD, not
PPC, could be the major active component for fat lysis
[7,23]. To address this speculation, the present study
assessed the effects of PPC alone, PPC formulation, and
SD on 3T3-L1 pre-adipocytes and differentiated 3T3-L1
adipocytes. Until now, the actions of PPC and SD could
not be directly compared, because PPC needs to be
emulsified with SD. However, we could apply PPC alone
using bovine serum albumin (BSA) as a carrier.
The specific aim of this study was to investigate the
mechanism of cell death induced by PPC and/or SD in
3T3-L1 pre-adipocytes. Furthermore, our study focused




L-a-phosphatidylcholine from soybean (P7443, ≥99%),
fatty acid-free BSA, insulin, dexamethasone, 3-isobutyl-
1-methylxanthine, and 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) were obtained
from Sigma-Aldrich (St. Louis, MO, USA). PPC was
added to cells as a complex with 0.4% BSA. Antibodies
against phospho-p38 mitogen-activated protein kinase
(MAPK) (Thr180/Tyr182) (CST-9211), phospho-c-Jun-
N-terminal kinase (JNK) (Thr183/Tyr185) (CST-9251),
and cleaved caspase-3 (CST-9661) were obtained from
Cell Signaling Technology (Danvers, MA, USA). Antibo-
dies against Bax (sc-526), Bcl-2 (sc-7382), caspase-9 (sc-
8355), caspase-8 (sc-7890), PARP (sc-7150), and actin
(sc-1616) were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). SD was obtained from New
Zealand Pharmaceuticals (Palmerston, New Zealand)
and a type of PPC formulation, Lipobean® (50 mg/ml,
containing 2.4% SD) was kindly supplied by AmiPharm
(Seoul, Korea).
Cell cultures
3T3-L1 pre-adipocytes were obtained from ATCC
(Rockville, MD, USA). The cells were grown in Dulbec-
co’s Modified Eagle’s Medium (DMEM) supplemented
with 10% bovine calf serum (BCS; Invitrogen, Carlsbad,
CA, USA), 50 μg/ml of streptomycin, and 50 μg/ml of
penicillin at 37°C in 5% CO2. After cells were reached
confluence, designated day 0, the cells were maintained
with differentiation-induction medium containing 0.5
mM 3-isobutyl-1-methylxanthine, 0.25 μM dexametha-
sone, 1 μg/ml insulin (MDI) and in DMEM with 10%
BCS for 4 days. Next, the culture medium was changed
to differentiation maintenance medium containing 1 μg/
ml insulin in DMEM with 10% BCS for 2 days.
MTT assay for cell viability
Cells (1 × 104 cells/well), seeded into 12-well plates for
24 h, were incubated with various concentrations of
PPC, SD, and Lipobean® (0-1 mg/ml) in DMEM con-
taining 10% fetal bovine serum (FBS) at 37°C in 5% CO2
for 24 h. After adding 100 μl/well of MTT solution (5
mg/ml), the plates were incubated for another 4 h.
Supernatants were then removed and the formazan crys-
tals were solubilized in 1 ml of dimethylsulfoxide. Opti-
cal density was determined at 540 nm using a
VERSAMax ELISA reader (Molecular Devices, Sunny-
vale, CA, USA).
Cell cycle analysis
Cells were trypsinized, adjusted to a density of 5 × 105 -
1 × 106 cells/tube, washed with ice-cold phosphate-buf-
fered saline (PBS), and re-suspended in 2 ml of ethanol.
After incubation at 4°C for 1 h, the ethanol was
removed and 100 μl of ribonuclease solution (10 mg/ml)
was added to each test tube. The tubes were then re-
incubated at room temperature for 30 min, and 500 µl
of analysis solution (37 mM EDTA and 0.1% Triton X-
100 in PBS) and 100 μl of propidium iodide solution
(400 μg/ml) were then added. Samples were stored in
the dark at 4°C and analyzed using a FACSCalibur flow
cytometer (Becton Dickinson, San Jose, CA, USA).
Western blotting
Cells were grown in 100 mm-diameter culture dishes,
serum-starved for 24 h, and treated with PPC, SD, and
Lipobean® at the indicated times. Cell lysates were pre-
pared in M-PER mammalian protein reagent (Pierce,
Rockford, IL, USA) containing a complete protease inhi-
bitor mixture (Roche, Mannheim, Germany). Samples
were separated by 12% sodium dodecyl sulfate-polyacry-
lamide gel electrophoresis (SDS-PAGE) and the resolved
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proteins were transferred to polyvinylidene fluoride
(PVDF) membranes, which were blocked with 5% dried
milk in PBS containing 0.5% Tween 20. The blots were
incubated with the appropriate primary antibodies at a
dilution of 1:1000. Membrane-bound primary antibodies
were detected using secondary antibodies conjugated
with horseradish peroxidase and chemiluminescent sub-
strate (Pierce). The images of the blotted membranes
were obtained using a LAS-1000 lumino-image analyzer
(Fuji Film, Tokyo, Japan).
Statistical analyses
Differences between groups were assessed with an analy-
sis of variance, followed by the Student’s t-test. P values
<0.01 were considered significant.
Results
Effects of PPC, SD, and Lipobean® on 3T3-L1 pre-
adipocyte viability
To examine cytotoxicity, 3T3-L1 pre-adipocytes were
treated with PPC, SD, and Lipobean® at 0-1 mg/ml for
24 h. Cell viabilities were measured by MTT assay (Fig-
ure 1A). PPC and Lipobean® at 0.1 mg/ml already
induced 3T3-L1 cell death in about 50% of the tested
populations, whereas SD at 0.1 mg/ml did not show cyto-
toxic activity. The morphology of 3T3-L1 cells after PPC,
SD, and Lipobean® treatment of 0.1 mg/ml is shown in
Figure 1B. After Lipobean® treatment, cell membrane
disturbance was evident because of cell death. However,
PPC-induced cell death produced different morphologi-
cal changes. We next tested the viability of normal
Figure 1 Effects of PPC on cell viabilities. (A) 3TC-L1 cells were treated with PPC, SD, Lipobean® at 0-1 mg/ml. (B) Morphology of 3T3-L1 cells
after 0.1 mg/ml of PPC, SD, Lipobean® treatment. Phase contrast photographs were taken using a digital video camera. (C) CCD-25Sk human
fibroblasts were treated with PPC, SD, Lipobean® at 0-1 mg/ml. After 24 h, cell viability was measured by MTT assay. The data represent the
mean ± standard deviation (S.D.) of triplicate assays expressed as percentages of the control. Each experiment was repeated independently at
least twice, and the representative results are shown. * P < 0.01 compared to the untreated control.
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human fibroblast cell line, CCD-25Sk, after treatment
with PPC, SD, and Lipobean®. PPC had little influence
on CCD-25Sk cell viability at the concentrations tested,
whereas SD and Lipobean® significantly decreased cell
viability by about 80% at 1 mg/ml (Figure 1C).
Recovery effects of media change on 3T3-L1 and CCD-
25Sk cell death
To examine the recovery from PPC, SD, or Lipobean®-
induced cell death, 3T3-L1 and CCD-25Sk cells were
supplied with fresh medium for 72 h and 96 h, after
which the cells were treated with PPC, SD, and Lipo-
bean® at 0.1 and 1 mg/ml. Cell viability was then mea-
sured by the MTT assay. PPC-induced 3T3-L1 cell
death was recovered in a minimal fashion, whereas
Lipobean®-induced cell death was dramatically abro-
gated (Figure 2A). On the other hand, SD- or Lipo-
bean®-induced CCD-25Sk cell death was not recovered
by a change of fresh media, whereas the viability of
PPC-treated CCD-25Sk cells was increased significantly
after medium change (Figure 2B).
PPC induces stress-regulated signaling pathway and
apoptotic pathway activation
Next, it was investigated whether p38 MAPK or JNK
could be activated by PPC, SD, and Lipobean® treat-
ment. PPC or SD (0.1 mg/ml) resulted in the activation
of p38 MAPK and JNK, while Lipobean® did not (Figure
3A). We further examined changes of the apoptotic
pathways induced by PPC, SD, and Lipobean® (Figure
3B). PPC clearly up-regulated Bax expression in 3T3-L1
cells, but had little influence on Bcl-2 expression. Thus,
PPC treatment substantially increased the Bax/Bcl-2
ratio. Caspases become active when they are cleaved
into processed fragments. In this experiment, we used
antibodies directed against the precursor forms of cas-
pase-9 and caspase-8. As shown in Figure 3B, PPC
cleaved and activated caspase-9 and caspase-8. An anti-
body directed against the cleaved form of caspase-3 was
also used, and the active form of caspase-3 increased
upon PPC treatment. Caspase-3 is believed to be the
most efficient PARP-cleaving caspase. Accordingly, we
found that the full-length PARP was cleaved after PCC
treatment. However, SD and Lipobean® did not show
these apoptotic changes.
Effects of PPC, SD, and Lipobean® on differentiated 3T3-
L1 cells
3T3-L1 pre-adipocytes were differentiated with MDI
medium for 6 days. Thereafter, differentiated 3T3-L1
cell viabilities were also tested after the treatment of
PPC, SD, and Lipobean® at 0-1 mg/ml for 24 h (Figure
4A). The results concerning differentiated 3T3-L1 cells
showed almost same tendency in 3T3-L1 pre-adipocytes.
Furthermore, cell cycle changes were analyzed by flow
cytometry (Figure 4B). Consistent with the cell viability
Figure 2 Effects of media change on cell recovery. (A) 3TC-L1 cells were treated with PPC, SD, Lipobean® at 0.1 mg/ml. (B) CCD-25Sk cells
were treated with PPC, SD, Lipobean® at 1 mg/ml. After 24 h, the media was removed and then was changed with fresh media. The cell
viability was measured by MTT assay after 72-96 h incubation in fresh media. The data represent the mean ± S.D. of triplicate assays expressed
as percentages of the control. Each experiment was repeated independently at least twice, and the representative results are shown. + P < 0.05,
* P < 0.01 compared to 24 h treated each group.
Li et al. Journal of Biomedical Science 2011, 18:91
http://www.jbiomedsci.com/content/18/1/91
Page 4 of 7
Figure 4 Effects of PPC, SD, and Lipobean® on differentiated 3T3-L1 cells. 3T3-L1 pre-adipocytes were differentiated for 6 days with MDI
media. (A) Differentiated 3T3-L1 cells were treated with PPC, SD, and Lipobean® at 0-1 mg/ml. After 24 h, cell viability was measured by the
MTT assay. The data represent the mean ± S.D. of triplicate assays expressed as percentages of the control. * P < 0.01 compared to the
untreated control (B) Differentiated 3T3-L1 cells were treated with PPC, SD, and Lipobean® at 0.1 mg/ml for 24 h. Cell cycle analysis of cells was
performed by a flow cytometer. (C) Differentiated 3T3-L1 cells were treated with PPC, SD, and Lipobean® at 1 mg/ml for 24 h. Whole cell lysates
were then subjected to Western blot anaysis with antibodies against Bax, Bcl-2, caspase-8, and PARP. Equal protein loadings were confirmed
using anti-actin antibody.
Figure 3 Effects of PPC, SD, and Lipobean® on apoptotic pathways. (A) After serum starvation, 3T3-L1 pre-adipocytes were treated with
PPC, SD, and Lipobean® at 0.1 mg/ml for 4 h. Whole cell lysates were then subjected to Western blot analysis with antibodies against phospho-
specific p38 MAPK and phospho-specific JNK. (B) After serum starvation, 3T3-L1 pre-adipocytes were treated with PPC, SD, and Lipobean® at 1
mg/ml for 24 h. Whole cell lysates were then subjected to Western blot analysis with antibodies against Bax, Bcl-2, caspase-9, caspase-8, cleaved
caspase-3, and PARP. Equal protein loadings were confirmed using anti-actin antibody.
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results, cell cycle disruption was observed when differ-
entiated 3T3-L1 cells were treated with PPC and Lipo-
bean® at 0.1 mg/ml. At a concentration of 1 mg/ml, we
could not detect cells after SD and Lipobean® treat-
ment, because they resulted in cell membrane lysis (data
not shown). For the same reason, the cell membrane
was disrupted, so protein was not detected in Western
blot analysis when differentiated 3T3-L1 cells were trea-
ted with 1 mg/ml of SD or Lipobean® (Figure 4C).
However, PPC treatment showed clear caspase-8 and
PARP cleavage, indicating that PPC induced apoptosis
of differentiated 3T3-L1 cells.
Discussion
In past years, nonsurgical lipolysis has increased [7], and
is the most economical use of subcutaneous injections to
reduce local fat via chemical lipolysis [8]. PPC injections
using a variety of PPC formulations are popular as a
treatment of local adiposities [24]. However, no product
intended for lipodissolution has yet been approved by the
Food and Drug Administration, Medicines and Health-
care Products Regulatory Agency (MHRA), because of
lack of data concerning safety and efficacy [24].
A PPC formulation generally used clinically consists of
PPC and SD [24]. It has been suggested that SD, the
detergent in the PPC formulation, is the active lipodis-
solving substance, and not PPC [25]. The main side
effects of injection of PPC formulations are relatively
minor, and include swelling, bruising, and sensitivity to
touch under the skin in areas with the lipodissolution
treatments [26]. However, since injection of SD causes
focal necrosis and inflammation in human lipomas [25],
it is entirely conceivable that the aforementioned side
effects of PPC formulations are due to SD, not to PPC
itself. Presently, we confirmed that SD induces cell
membrane lysis, resulting in necrosis. Interestingly, how-
ever, the results of the MTT assay clearly indicate that
PPC alone without SD induced cell death of 3T3-L1
pre-adipocytes. The results also demonstrated that the
effects of inducing 3T3-L1 cell death by PPC formula-
tion did not depend only on SD. In addition, our flow
cytometric experiments showed that Lipobean® treat-
ment resulted in cell membrane lyses because of SD
(data not shown). A large discrepancy in the extent of
cell viability was presently evident between 0.5 mg/ml
and 1 mg/ml Lipobean® (Figure 1C). These Lipobean®
concentrations may be at the threshold for membrane
stability.
In agreement with our study, PPC formulation and SD
induce the lysis of various cell types including pre-adi-
pocytes, normal human fibroblasts, endothelial cells, and
skeletal muscle cells in a nonspecific manner [7]. These
results are very important because the injection of PPC
formulation may cause tissue necrosis. However, in our
study, PPC alone did not induce cell death of CCD-
25Sk normal fibroblasts. It is very important that PPC
reduced only adipocyte viability specifically, but did not
decrease cell viability of other cell types such as fibro-
blasts. On the other hand, PPC formulation and SD
induced cell death of both cell types. These results indi-
cate that the SD constituent of PPC formulations initi-
ates the cell lysis, leading to cell death. Clearly, more
study is required to confirm this suggestion.
PPC induces apoptosis in cells such as colon cancer
cells [27], vascular endothelial cells [28], and macro-
phages [29]. Phosphorylation of stress-activated protein
kinase pathways [30] and cleavage of caspases are main
pathways of apoptosis [31]. Especially, the death-recep-
tor inducing activation of caspase-8 and mitochondrial
pathways is the key point of apoptotic pathways [32]. In
the present study, PPC induced not only the activation
of p38 and JNK, but also the cleavage of caspase-8, -9,
-3, and PARP in 3T3-L1 pre-adipocytes (Figure 3). Spe-
cifically, PPC treatment unequivocably activated cas-
pase-8 in both 3T3-L1 pre-adipocytes and differentiated
3T3-L1 cells (Figures 3B and 4C). The caspase-8 path-
way is intimately involved in CD95-mediated apoptotic
cell death [33,34]. These results indicate that PPC-
induced apoptosis may be due to increased death recep-
tor activations. This possibility should be further exam-
ined to elucidate PPC-induced apoptotic pathways.
Furthermore, the increase of sub-G1 fraction is an indi-
cation of apoptosis that naturally occurs in cells [35], and
the sub-G1 phase in the cell cycle is increased in apopto-
tic cell death [36]. Therefore, to characterize apoptotic
cells upon treatment of PPC, SD, and PPC formulation,
flow cytometric analysis was presently performed. Treat-
ment with 0.1 mg/ml PPC treatment increased sub-G1
phase in 3T3-L1 adipocytes. These results favor the view
that PPC induces apoptosis of 3T3-L1 cells.
Conclusions
In conclusion, it can be suggested that PPC alone has an
apoptotic effect on 3T3-L1 adipocytes. Thus, PPC with-
out SD should be used for the potential drug of treat-
ment of local fat to avoid the main side effects of PPC
formulation. For this purpose, a new drug delivery
method will be needed for a PPC formulation without
SD. Because PPC may form liposomal vesicles in aqu-
eous solution, PPC liposomes could be adequate for a
new drug delivery method.
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